Evidence map›Paper›PMID 25117960›Full record

ReviewJournal of acquired immune deficiency syndromes (1999)2014

HIV and noncommunicable cardiovascular and pulmonary diseases in low- and middle-income countries in the ART era: what we know and best directions for future research.

Gerald S Bloomfield, Prateeti Khazanie, Alison Morris, Cristina Rabadán-Diehl, Laura A Benjamin, David Murdoch, Virginia S Radcliff, Eric J Velazquez, Charles Hicks

Abstract readReview
In one paragraph

Review in Journal of acquired immune deficiency syndromes (1999), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Physical activity and hypertension amongst HIV-positive and HIV-negative populations in rural South Africa.Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gerald S Bloomfield*Division of Cardiology, Department of Medicine and Duke Clinical Research Institute, Duke University, Durham, NC; †Duke Global Health Institute, Duke University, Durham, NC; ‡Departments of Medicine and Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA; §National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD; ‖Institute of Infection and Global Health, University of Liverpool, Liverpool, United Kingdom; ¶Malawi-Liverpool-Wellcome Major Overseas Clinical Research Programme, College of Medicine, University of Malawi, Blantyre, Malawi; #Divisions of Pulmonary and Critical Care Medicine; and **Infectious Diseases, Department of Medicine, Duke University, Durham, NC.
Prateeti Khazanie
Alison Morris
Cristina Rabadán-Diehl
Laura A Benjamin
David Murdoch
Virginia S Radcliff
Eric J Velazquez
Charles Hicks

Funding

Vascular Subphenotypes of Lung DiseaseP01HL103455 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GLADWIN, MARK T · 2011 to 2020
$26.1M
Prevalence & Pathogenesis of Pulmonary Disease in a Large Multicenter HIV CohortR01HL090339 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MORRIS, ALISON · 2007 to 2011
$4.0M
Translational evaluation of aging, inflammation, and HIV in lung dysfunctionR01HL120398 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MORRIS, ALISON · 2013 to 2017
$3.4M
Risk Factors for Atherosclerosis among Patients with Heart Failure in KenyaK01TW008407 · FIC · DUKE UNIVERSITY · PI BLOOMFIELD, GERALD SAMUEL · 2011 to 2014
$490k
FIC NIH HHS K01 TW008407FIC NIH HHS K01TW008407NHLBI NIH HHS P01 HL103455NHLBI NIH HHS P01HL103455NHLBI NIH HHS R01 HL090339NHLBI NIH HHS R01HL090339NHLBI NIH HHS R01 HL120398Wellcome Trust 089672/Z/09/AWellcome Trust 100890
6 · The paper itself

Abstract

With the advent of effective antiretroviral therapy (ART), HIV is becoming a chronic disease. HIV-seropositive (+) patients on ART can expect to live longer and, as a result, they are at risk of developing chronic noncommunicable diseases related to factors, such as aging, lifestyle, long-term HIV infection, and the potential adverse effects of ART. Although data are incomplete, evidence suggests that even in low- and middle-income countries (LMICs), chronic cardiovascular and pulmonary diseases are increasing in HIV-positive patients. This review summarizes evidence-linking HIV infection to the most commonly cited chronic cardiovascular and pulmonary conditions in LMICs: heart failure, hypertension, coronary artery disease/myocardial infarction, stroke, obstructive lung diseases, and pulmonary arterial hypertension. We describe the observed epidemiology of these conditions, factors affecting expression in LMICs, and key populations that may be at higher risk (ie, illicit drug users and children), and finally, we suggest that strategic areas of research and training intended to counter these conditions effectively. As access to ART in LMICs increases, long-term outcomes among HIV-positive persons will increasingly be determined by a range of associated chronic cardiovascular and pulmonary complications. Actions taken now to identify those conditions that contribute to long-term morbidity and mortality optimize early recognition and diagnosis and implement effective prevention strategies and/or disease interventions are likely to have the greatest impact on limiting cardiovascular and pulmonary disease comorbidity and improving population health among HIV-positive patients in LMICs.

Indexed as

Anti-Retroviral AgentsAntiretroviral Therapy, Highly ActiveCardiovascular DiseasesDeveloping CountriesHIV InfectionsHumansLung DiseasesResearchRisk FactorsAnti-Retroviral Agents

Identifiers

PMID25117960
PMCPMC4133739

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.